Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Vaxart, Inc.ex99-1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


 

FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2016


 

Aviragen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware

001-35285

59-1212264

(State or other jurisdiction

of incorporation)

(Commission 

File Number)

(IRS Employer

Identification No.)

     
     
  2500 Northwinds Parkway, Suite 100  
  Alpharetta, GA 30009
  (Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (678) 221-3350

 

Not Applicable

(Former name or former address, if changed since last report)


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 


Item 8.01 Other Events

 

On October 10, 2016, Aviragen Therapeutics, Inc. (the “Company”) issued a press release announcing it will host a Key Opinion Leader breakfast on Thursday, October 13, 2016 from 8:30 a.m. to 10:30 a.m. ET in New York. A copy of the press release is attached as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

99.1          Press release dated October 10, 2016.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Aviragen Therapeutics, Inc.

Date: October 10, 2016

/s/ Joseph M Patti

 

Name:

Joseph M Patti

 

Title:

Chief Executive Officer and President

   

(Duly Authorized Officer)


 

EXHIBIT INDEX

Exhibit

Number

 

Description

99.1

 

Press release dated October 10, 2016.